Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study-Reference-Cited by-同舟云学术

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study

Published:2017-06-07 Issue:7 Volume:69 Page:1020-1029
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Marzo-Ortega H.¹,Sieper J.²,Kivitz A.³,Blanco R.⁴,Cohen M.⁵,Martin R.⁶,Readie A.⁶,Richards H. B.⁷,Porter B.⁶,

Affiliation:

1. Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds UK

2. University Clinic Benjamin Franklin; Berlin Germany

3. Altoona Center for Clinical Research; Duncansville Pennsylvania

4. Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla-IDIVAL; Santander Spain

5. McGill University; Montreal Canada

6. Novartis Pharmaceuticals Corporation; East Hanover New Jersey

7. Novartis Pharma AG; Basel Switzerland

Funder

Novartis Pharma AG

Publisher

Wiley

Subject

Rheumatology

Reference40 articles.

1. Quality indicators, guidelines and outcome measures in ankylosing spondylitis;Zochling;Clin Exp Rheumatol,2007

2. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis;Zochling;Ann Rheum Dis,2006

3. Anti-TNF-α treatment and spondyloarthropathies;Braun;Harefuah,2002

4. TNF antagonists for ankylosing spondylitis;Drug Ther Bull,2005

5. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years: early clinical response predicts long-term outcome;Baraliakos;Rheumatology (Oxford),2011

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?;Autoimmunity Reviews;2024-09

2. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis;Frontiers in Immunology;2024-07-15

3. Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis;Rheumatology and Therapy;2024-06-25

4. Dynamics of T-cell receptor repertoire in patients with ankylosing spondylitis after biologic therapy;International Immunopharmacology;2024-01

5. Efficacy of pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases;RMD Open;2023-12